Key result
Bezafibrate and fenofibrate similarly lower canine triglycerides, with ~/dL greater reduction alongside low-fat diet.
Why the study?
No prior clinical study had directly compared the triglyceride- and cholesterol-lowering effects of bezafibrate and fenofibrate in dogs with fasting hyperlipidemia or evaluated the additional benefit of concurrent low-fat dietary management under comparable clinical conditions.
Does bezafibrate compared with fenofibrate, with or without concurrent low-fat dietary management, reduce fasting serum triglyceride and total cholesterol concentrations in dogs with idiopathic hyperlipidemia?
Cohort (n=65)
non-randomized and determined by clinician and owner discretion
No
Does bezafibrate compared with fenofibrate, with or without concurrent low-fat dietary management, reduce fasting serum triglyceride and total cholesterol concentrations in dogs with idiopathic hyperlipidemia?
In dogs with idiopathic fasting hyperlipidemia, bezafibrate and fenofibrate provide comparable short-term triglyceride reduction and good biochemical tolerability, while concurrent low-fat dietary management significantly enhances triglyceride lowering.
Answers are grounded in this paper and cite their sources.
Bezafibrate or fenofibrate plus low-fat diet was associated with greater canine triglyceride reduction; leaves open optimal agent choice and need for randomized confirmation.
The aim of this retrospective study was to compare the triglyceride- and cholesterol-lowering effects of bezafibrate and fenofibrate in dogs with fasting hyperlipidemia and to evaluate the additional benefit of concurrent low-fat dietary management. To our knowledge, this is the first clinical study to directly compare these two fibrates in dogs treated under comparable clinical conditions. Sixty-five client-owned dogs were classified into six groups according to treatment: bezafibrate monotherapy, bezafibrate with a low-fat diet, fenofibrate monotherapy, fenofibrate with a low-fat diet, low-fat diet alone, and untreated control. Changes in serum triglyceride and total cholesterol concentrations from baseline to the final follow-up were analyzed, and hepatic and renal biochemical markers were assessed to evaluate short-term tolerability. Both bezafibrate and fenofibrate produced marked reductions in serum triglyceride concentrations, with no significant difference between the two fibrates. Dogs receiving low-fat dietary management showed significantly greater triglyceride reduction than those managed without low-fat dietary management, whereas total cholesterol changes did not differ significantly between treatment groups. Treatment duration was not significantly associated with the magnitude of lipid reduction. Hepatic and renal biomarkers remained stable during the follow-up period, and no serious adverse events were recorded. These findings indicate no significant difference in short-term triglyceride reduction between bezafibrate and fenofibrate in the studied population. Concurrent low-fat dietary management was associated with greater triglyceride reduction and should be considered an important component of treatment. Further prospective studies with larger populations and longer follow-up periods are needed to confirm long-term safety and efficacy..
No takes yet. Share an insight, caveat, or question.
Jeong et al. (2026) conducted a cohort in canine fasting idiopathic hyperlipidemia (n=65). Bezafibrate (5 mg/kg PO q24h) or fenofibrate (10 mg/kg PO q24h), with or without prescription low-fat diet vs. Low-fat diet alone or untreated control on pre-existing commercial diet (>10% crude fat) was evaluated on Absolute change in fasting serum triglyceride (TG) and total cholesterol (TChol) concentrations from baseline to final follow-up (η² = 0.185 (three-group ANOVA); AB vs CD p = 0.777, p=0.002 (overall); 0.777 (bezafibrate vs fenofibrate)). Bezafibrate and fenofibrate both markedly reduced canine serum triglycerides, with greater reduction when combined with a low-fat diet.
Synapse has enriched 10 related papers. Consider them for comparative context: